the complexity of host's effective immune response against a polymorphic parasitic disease by Gabriel , AM et al.
Review Article
Cutaneous Leishmaniasis: The Complexity of Host’s Effective
Immune Response against a Polymorphic Parasitic Disease
Áurea Gabriel , Ana Valério-Bolas, Joana Palma-Marques, Patrícia Mourata-Gonçalves,
Pedro Ruas , Tatiana Dias-Guerreiro , and Gabriela Santos-Gomes
Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de
Lisboa (UNL), Rua da Junqueira 100, 1349-008 Lisboa, Portugal
Correspondence should be addressed to Gabriela Santos-Gomes; santosgomes@ihmt.unl.pt
Received 31 December 2018; Revised 5 October 2019; Accepted 22 October 2019; Published 1 December 2019
Academic Editor: Kurt Blaser
Copyright © 2019 Áurea Gabriel et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This review is aimed at providing a comprehensive outline of the immune response displayed against cutaneous leishmaniasis (CL),
the more common zoonotic infection caused by protozoan parasites of the genus Leishmania. Although of polymorphic clinical
presentation, classically CL is characterized by leishmaniotic lesions on the face and extremities of the patients, which can be
ulcerative, and even after healing can lead to permanent injuries and disfigurement, affecting significantly their psychological,
social, and economic well-being. According a report released by the World Health Organization, the disability-adjusted life years
(DALYs) lost due to leishmaniasis are close to 2.4 million, annually there are 1.0–1.5 million new cases of CL, and a numerous
population is at risk in the endemic areas. Despite its increasing worldwide incidence, it is one of the so-called neglected tropical
diseases. Furthermore, this review provides an overview of the existing knowledge of the host innate and acquired immune
response to cutaneous species of Leishmania. The use of animal models and of in vitro studies has improved the understanding
of parasite-host interplay and the complexity of immune mechanisms involved. The importance of diagnosis accuracy
associated with effective patient management in CL reduction is highlighted. However, the multiple factors involved in CL
epizoology associated with the unavailability of vaccines or drugs to prevent infection make difficult to formulate an effective
strategy for CL control.
1. Introduction
Leishmaniases are anthroponotic and zoonotic diseases of
global public health significance caused by obligatory intra-
cellular digenetic parasites of the genus Leishmania [1–3].
These parasites are transmitted to human beings and mam-
malian hosts by the bite of infected sand flies of the Phleboto-
mus genus in the Old World and Lutzomyia in the New
World, generating cutaneous or visceral leishmaniasis [4,
5]. More than 20 Leishmania species have been identified
worldwide, according to the WHO [1, 5]. Several species of
Leishmania, belonging to both Leishmania and Viannia sub-
genus, cause CL in humans, including L. tropica, L. major,
and L. aethiopica in the Old World and also L. mexicana, L.
amazonensis, L. venezuelensis, L. braziliensis, L. shawi, L.
guyanensis, L. panamensis, and L. peruviana that are only
found in the New World [2, 5, 6] (Table 1). Differences
among Leishmania species can lead to diverse clinical mani-
festations and therapeutic responses [7–9]. The knowledge
about the complex interactions between these species and
the respective hosts, their geographical distribution, histo-
pathological effects, clinical lesions, and immune evasion still
need to be deepened [2, 4, 5, 7]. In general, cutaneous species
cause skin and mucous membrane lesions, which can persist
for a long time in patients suffering from the disease and can
also relapse during treatment [10–12]. Some CL patients can
develop permanent injuries, which can leave them disfigured
and stigmatized for life [11, 13, 14]. Thus, this review is
aimed at providing a comprehensive outline of the immune
response generated against the cutaneous species of Leish-
mania, evidencing the need for further studies able to deepen
the understanding of protective immune mechanisms and
pointing out opportunities that might be explored to further
reduce CL threat.
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2. Cutaneous Leishmaniasis Has a Wide
Geographic Distribution and Present
Polymorphic Clinical Features
Cutaneous leishmaniasis is considered the most common
form of a Leishmania infection, affecting approximately 0.7
million to 1.2 million human beings [1, 14, 15]. This clinical
form is prevalent in more than 90 countries with a proven
endemic transmission in tropical and subtropical areas of
the world, including rural, rainforests, arid areas, semiurban,
and urban areas [4, 15, 16]. According to Maia-Elkhoury
et al. [16], increased number of cases may be attributed to
behavioral and environmental changes, determined mainly
by climate, social, and economic conditions that influence
Leishmania transmission.
CL is present in the southern USA, where occasional
cases were reported in the States of Texas and Oklahoma,
Central and South America, being the majority of CL cases
reported in Brazil and Peru [16–18], and in the Old World,
at North and East Africa, Middle East, and Western and
South Asia [18–20] (Figure 1). In these areas, some cities
show very high notification rates for new CL cases, like
Aleppo (Syria, Western Asia) with around 12.000 new cases
each year [19–21].
Leishmania lesions without pain or pruritus are com-
mon, but in some patients can be painful, especially if ulcer-
ative lesions become secondarily infected with bacteria or if
these lesions are near a joint [22]. CL may range between a
limited form, presenting only one or few localized lesions,
to a disseminated form with multiple lesions (Table 2),
including hypodermal, verrucous, sporotrichoid, impetigoid,
hemorrhagic, erysipeloid, chancriform, lupoid, papular,
psoriasiform, and ulcer-crusted lesions [11, 23, 24].
The lesions may start out as nodules in approximately
20% of cases during acute infections and persist in chronic
infection [1]. Depending on the clinical type and stage, the
epidermis may be overlying a dense dermal infiltrate, con-
taining predominantly histiocytes, lymphocytes, and plasma
cells [25]. Several patients with American CL may develop
regional lymphadenopathy, occasionally bubonic, nodular
lymphangitis (sporotrichoid-like subcutaneous nodules),
and satellite lesions [1].
In epidemic regions of Western Asia, where cases of L.
tropica advanced to aggressive and prolonged disease
courses, the lesions impinged and possibly hindered the
function of vital sensory organs, including olfactory percep-
tion and vision [19].
3. Competence of Innate and Acquired Immune
Response Determines Infection Outcome and
Cutaneous Leishmaniasis Severity
The dissemination and persistence of Leishmania parasites
in the immunocompetent host depends on continuous para-
site strategies able to modulate and subvert innate and adap-
tive immune response [25–27]. According to in vitro studies,
the host genetic background, Leishmania species, and differ-
ent parasite isolates can influence immune response [28].
Increasing interest in studying the immune response against
cutaneous species of Leishmania in different animal models
(such as susceptible BALB/c mice, resistant C57BL/6 mice,
and nonhuman primates) has contributed to an improved
understanding of specific parasite-host interactions and
highly complex pathways of immune mechanisms underly-
ing CL immunopathology [25, 29, 30]. However, a full





Figure 1: Worldwide distribution of cutaneous leishmaniasis, adapted from [1, 15, 18].
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or inactivated in CL patients is crucial for the reduction of
disease incidence to a level that would have a minimal
impact on public health.
Immune defense is characterized by two principal
mechanisms, the innate immune response that is activated
early during the primary stage of the infection and the
adaptive immune response, which is the second line
response. The bridge between these two responses is
accomplished by antigen-presenting cells (APCs) and by
cytokines released into the microenvironment by effector
immune cells.
3.1. Inactivation of a Complement System Seems to Favor the
Establishment of Parasite Infection. The complement system
plays a critical role in the innate immune defense. Plasma
proteins that constitute the complement system are impli-
cated in the activation of classical (CP), alternative (AP),
and lectin pathways (LP). Complement activation triggers
the stimulation of proteolytic cascades, generating different
molecules, such as anaphylatoxins, opsonins, and the mem-
brane attack complex. At the end of the complement cascade,
pathogens undergo lysis and opsonization and also an
inflammatory response occurs.
In vitro studies have shown that noninfective Leish-
mania promastigotes are susceptible to complement-
mediated lysis and that infective metacyclic promastigotes
can actively resist [31].
Once in the dermis of mammals, infective promastigotes
activate the complement system, and then, the parasite first
survival mechanism comes into action, inhibiting comple-
ment cascade [32, 33].
Manipulation of the complement cascade is achieved
through the inactivation of opsonins to promote macrophage
(MΦ) attraction [26, 30]. Previous studies have shown that
LP is efficiently activated, since mannose-binding lectin, a
protein that binds to the lipophosphoglycan of several micro-
organisms, including Leishmania, initiates the proteolytic
cascade causing pathogen lysis [33–35]. Moreover, LP activa-
tion triggers C3-convertase that converts C3 in C3b directing
AP activation [34, 36].
Infective Leishmania promastigotes have developed
mechanisms to subvert AP activation [37].
Table 2: Clinical presentation and delayed-type hypersensibility (DTH) of cutaneous Leishmania species in the world, adapted from
[2, 82, 90].
Subgenus Species Main clinical presentation DTH (skin test)
Leishmania
L. major Localized —
L. tropica Localized DTH +






























L. peruviana One or few lesions —
L. venezuelensis





L. pifanoi Diffuse —
L. guyanensis
Single and multiple skin lesions




Single and multiple skin lesions
Cases of multiple lesions, clearly due
to metastases, are occasionally seen
—
—
L. colombiensis Single and multiple skin lesions —
L. naiffi Localized —
L. lainsoni Localized —
L. lindenbergi Localized —
L. garnhami Localized —
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It was early found that the Leishmania surface glyco-
protein captures C3b molecules [26, 30]. Upon the binding
of C3 molecules to the glycoprotein of 63 kDa (gp63), C3b
becomes inactivated (iC3b), which prevent the generation
of C3-convertase [37]. iC3b that remains attached to the
parasite surface is recognized by the complement
receptor-3 that triggers promastigote phagocytosis by MΦ
(Figure 2). Once uptake by MΦ, parasite differentiates into
the amastigote form, which have the right conditions to
initiate replication [26, 30].
Complement activation by L. mexicana membrane
components was reported to cause the depletion of com-
plement factors [37]. Complement exhaustion can drive
the complement-independent parasite uptake by polymor-
phonuclear neutrophil granulocytes (PMNs), which can pro-
long parasite survival [30, 32]. Thus, the innate immune
response drove by the complement system of the host seems
to negatively impact on CL caused by L. mexicana.
Even so, previous studies in BALB/c mice showed that
complement can diminish the spreading of L. amazonensis
parasites in cutaneous lesions [38] and in vitro studies
revealed that L. tropica amastigotes were susceptible to com-
plement lysis [39], suggesting that during infection amasti-
gotes can be susceptible to the complement system.
3.2. Neutrophils Seem to Have a Dual Effect Delaying the
Early Establishment of Infection and Later One Favoring
Lesion Pathology. Shortly after mammal infection by sand
fly inoculation, infective metacyclic promastigotes have to
evade host innate immunity to survive [25, 30].
Polymorphonuclear neutrophils (PMNs) are the first
host cells that migrate to the site of Leishmania infection
(as well as tissue MΦ), probably in response to sand fly saliva
[40–42] that is inoculated together with parasites. These
short-lived cells armed with a set of intracellular and extra-
cellular mechanisms can arrest and kill pathogens [30, 32].
When encountering Leishmania, PMNs can internalize
the parasite, generate an array of intracellular and extracel-
lular microbicidal factors, such as reactive oxygen species,
exocytosis of granule content rich in serine proteases that
can damage the parasite membrane, and also emit web-
like sticky structures (neutrophil extracellular traps (NETs))
to the extracellular space which can entrap and inactivate
parasites, producing a proinflammatory environment [30–
32]. However, despite the diverse mechanisms that PMNs
have to contain pathogens, Leishmania parasites can sur-
vive, establishing infection and causing disease [30, 32, 33].
In the model of PMN intracellular infection, neutrophils
can be used as “Trojan horses” assuring parasite survival and
internalization by macrophages (MΦ), the definitive host
cells, which also avoid the activation of MΦ killing mecha-
nisms. Other studies performed with L. major revealed that
mouse apoptotic PMNs can release viable parasites in the
vicinity of surrounding MΦ, favoring parasite uptake by
MΦ (Trojan rabbit mechanism) [28, 43].
The role of PMNs in controlling the dissemination of
parasites at the early phase of cutaneous Leishmania infec-
tions has been studied in vitro and in experimental animal
models [32]. An in vitro study showed that mouse neutro-
phils exposed to L. guyanensis, L. shawi, and L. amazonensis
produced superoxide, released enzymes in the extracellular
space, and generated NETs. However, L. guyanensis and L.
shawi inhibited enzymatic activity and L. amazonensis
reduced the NET emission, pointing towards the modulation
of PMN extracellular effector mechanisms by cutaneous spe-
cies of Leishmania [32]. Recent studies performed in the
mouse model showed that PMN depletion accelerated the
spreading of L. major and L. amazonensis parasites, leading
to a more severe foot-pad swelling, which indicates that
PMNs have a role in restraining parasite infection and in
controlling the development of cutaneous lesions [44, 45].
Neutrophils seem to recognize these parasites through pat-
tern recognition receptor- (PRR-) dependent mechanisms,
such as toll-like receptor (TLR) 2, thereby activating down-
stream pathways that could compromise parasite survival
[32, 46, 47].
After in vitro parasite stimulation, bloodstream PMNs
from L. braziliensis-symptomatic patients were not more
microbicidal than PMNs obtained from healthy subjects
but presented a predominately proinflammatory profile, pos-
sibly influencing microenvironment and leukocyte recruit-
ment [27, 47]. When in contact with parasites, PMNs
isolated from healthy blood donors and from patients with
American CL released NETs that contained and retained par-
asites, promoting its destruction as well as stimulated MΦ
activity in order to control parasite infection [48, 49]. It was













Figure 2: Inoculation of Leishmania promastigotes in the host
dermis by the sand fly triggers the activation of the complement
cascade. C3 convertase undergoes proteolytic cleavage, giving
origin to the complement factors C3a and C5a. These chemotactic
factors attract neutrophils (N) and macrophages (MΦ) to the
infection site and induce the expression of the respective
receptors. On the parasite membrane, the surface glycoprotein of
63 kDa (gp63) can convert C3b to the inactive form (C3bi), which
avoids the assembly of the lytic complex (MAC) on the parasite
surface. In turn, C3bi binds to the MΦ receptor (RC3), promoting
fast parasite phagocytosis.
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exposed apoptotic or necrotic neutrophils withMΦ drove the
initial MΦ-parasite infection, determining the infection out-
come [50]. Taken together, these findings highlight the cru-
cial role of PMNs in early infection, controlling cutaneous
Leishmania parasites and delaying infection establishment
and the progress of lesions [32, 50].
Neutrophils are present in unhealing cutaneous lesions,
and recent studies performed in both humans and mice have
shown that PMN infiltrates in cutaneous lesions induce
immune-mediated tissue pathology [28, 40, 51].
Furthermore, PMN can present heterogeneous func-
tional activity against different cutaneous Leishmania species
and within the same species, indicating specific parasite
immune recognition [9]. Different L. braziliensis isolates
can promote specific activation of human PMNs. PMNs
can inactivate Leishmania parasites or can favor infection,
hosting viable infective parasites that can be delivered to
the host cell. These findings support the hypothesis that
PMNs can select the most infective parasites and inactivating
the less virulent ones, which can generate novel avenues to
explore the development of strategies underlying the modu-
lation of PMN recruitment and activity that can direct lesion
healing [52].
Although widely recognized as not having a key role in
parasitic diseases caused by protozoa, in vivo studies
highlighted eosinophil recruitment to L. amazonensis and
L. major lesions [53–55]. It was also described that L. brazi-
liensis patients that were in the early phase of lymphadenop-
athy exhibited cellular infiltrates enriched in eosinophils.
[53]. Moreover, in L. mexicana early infection, eosinophils
have been observed within the proximity of degranulating
mast cells at the parasite inoculation site [56], pointing
towards the occurrence of crosstalk between these two cells
that could favor parasite clearance.
3.3. Cytotoxic Innate Cells Can Aid in the Control of Dermal
Infection. After PMN recruitment, natural killer (NK) cells
are also recruited in the early stage of Leishmania infection
[25, 31]. NK cells are large granular leukocytes that play a
key role in the innate immune response [57]. These cells
are crucial in defining disease severity, restricting early para-
site dissemination, and mediating direct lysis of parasitized
cells, conferring protective immune response against Leish-
mania infection. Studies performed in the mouse model with
L. amazonensis and L. major show the increase of parasite
burden as a direct consequence of NK cell depletion [58–
60]. These cells early release proinflammatory cytokines,
such as interferon- (IFN-) γ that favors the differentiation
of CD4+ Th1 cells and together with tumor necrosis factor-
(TNF-) α activates the MΦ killing machinery [33, 59, 60].
However, it seems that Leishmania parasites have some
mechanisms directed to suppress NK activity [58–60].
Studies performed in L. major-infected mice have dem-
onstrated that NK cells exhibit a strong activation that peaks
at 12 h to 48h after infection, after which a steady decline
tends to occur [61]. Some authors associate this suppression
with the ability of this parasite to inhibit the production by
neutrophils of NK cell-attracting chemokine IP-10 (CXCL9),
which can prevent the activation of NK cells, therefore avoid-
ing a continuous onset of NK cells from the bloodstream
[62]. Furthermore, it was demonstrated that L. major pro-
mastigotes, the respective crude antigen, and gp63 can inhibit
IFN-γ production by NK cells. gp63 seems to be able to bind
to human NK cells, inhibiting cell’s ability to produce IL-2
and downregulate some of the NK cell receptors, such as
CD16 and CD56 [63]. In the case of L. tropica and L. amazo-
nensis amastigotes, suppression of NK cell activity seems to
be associated with low levels of IL-12. This interleukin
released by DC determines NK cell activation. In human
beings, it has been demonstrated an increase of CD56+NK
cells in sites of healing lesions [64], thus suggesting a protec-
tive role of these cells in human leishmaniasis.
Although it was demonstrated that NK cells protect
against CL, some studies indicate that these cells play a minor
role [31, 53]. Thus, it is possible that NK cells can aid the
immune system fighting against infection, but the involve-
ment of these cells is still poorly studied in human CL and
remains controversial in experimental murine leishmaniasis
[53, 54, 65]. However, NK cell activity differs between
patients with L. mexicana localized (LCL) and diffuse
(DCL) CL. Reduced NK cell numbers in DCL patients asso-
ciated with TLR downexpression and low cytokine produc-
tion can be related to disease severity [65].
Therefore, it is possible that the regulation of NK cells can
lead to a new opportunity for targeting CL control.
3.4. Antigen-Presenting Cells Have a Key Role in Directing T
Cell Effector Activity. Promastigotes are also taken up by
MΦ that are the final host cells for Leishmania parasites
[56]. In spite of being the parasite preferential host cells, since
it is inside MΦ that replicates, these cells still are an immune
barrier that parasites must overcome to persist in the host
[26, 30]. Within MΦ phagolysosome, promastigote forms
undergo morphological differentiation into small and non-
motile amastigotes able to resist to host cell killing mecha-
nisms and survive under mammal high temperature (when
compared to the sand fly) [30, 56]. Amastigotes replicate
and promote the chronicity of cutaneous infection within
dermal MΦ [30, 56]. Leishmania parasites can induce MΦ
differentiation into two distinct phenotypes: M1 and M2
[30] (Figure 3). M1-MΦ, also called classically activated
MΦ, are stimulated by the proinflammatory cytokines IFN-
γ and TNF-α. These cytokines induce the expression of nitric
oxide (NO) synthase 2 (NOS2), which degrades arginine into
OH-arginine and subsequently into NO and citrulline [31,
66, 67]. NO can be further metabolized to other reactive
nitrogen species, while citrulline can enter in the citrulline–
NO cycle and synthesize NO [66–68]. This mechanism is
responsible for NO-dependent leishmanicidal activity, which
plays a key role against Leishmania infection [67, 68].
Although M1-MΦ response usually leads to parasite control,
it also promotes necrosis of cutaneous lesions in consequence
of an intense immune response that favors the development
of severe wounds [69].
M2-MΦ, also known as alternatively activated MΦ,
can be induced by different immunomodulators, including
MΦ colony-stimulating factor (M-CSF), interleukin- (IL-)
4, and IL-1. According to stimulation, M2-MΦ can be
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phenotypically identified as M2a, M2b, M2c, or M2d,
which seems to be involved in different immune activities.
M2-MΦ activate the arginine pathway by expressing
arginase, an enzyme that hydrolyzes arginine into urea and
ornithine. Ornithine is further metabolized into polyamine
and proline, which induce cellular proliferation, collagen
production, and tissue repair [68–70].
Moreover, in 2007, Odegaard et al. [71] reported that per-
oxisome proliferator-activated receptor- (PPAR-) γ has a role
in the maturation of alternatively activated MΦ and showed
that disruption of PPAR-γ in myeloid cells prejudices M2-
MΦ activation [71, 72]. In fact, several studies obtained evi-
dence that M2-MΦ are associated with Leishmania infection.
In the case of CL, the involvement of PPAR-γ in M2-MΦ
activation was only reported to L. major, L. amazonensis,
and L. mexicana infection [30, 37, 69].
Although activation of M1-MΦ by both IFN-γ and
TNF-α results in control of infection, this observation
might not be a true predictor of disease progression to
all cutaneous species of Leishmania, since it is also
reported that IFN-γ-activated MΦ (M1-MΦ) are not able
to incapacitate L. amazonensis amastigotes, favoring para-
site survival [30, 50]. In resistant mice, L. major infected
MΦs will trigger T helper 1 (Th1) cells, directing the pro-
duction of IFN-γ and, consequently, activating the inducible
nitric oxide synthase (iNOS) and leading to differentiation of
M1-MΦ [66, 73]. This will lead to parasite inactivation and
slow down parasite dispersion [74].
Furthermore, in patients with diffuse CL due to L. ama-
zonensis, arginase, polyamines, and prostaglandin E2, a lipid
compound derived from fatty acids commonly associated
with inflamed tissues seems to lessen local inflammatory
immune response when compared with patients with local
CL [75]. Thus, it is possible that together, these mediators
favor the development of diffuse CL.
More recent studies have demonstrated that the arginase
of L. amazonensis can mediate the posttranscriptional regu-
lation of MΦmicroRNAs [75]. The absence of parasitic argi-
nase seems to favor NOS2 upregulation and the consequent

































Figure 3: Differentiation of macrophage effector mechanisms against cutaneous species of Leishmania influences parasite fate and disease
severity. IL: interleukin, IFN: interferon, MΦ: macrophages, NO: nitric oxide, PPAR: peroxisome proliferator-activated receptor.
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inactivation. Besides, a further study by Badirzadeh et al.
did not found significant correlations between the activity
of L. major arginase and the number, size, and duration
of patient lesions [76, 77]. On the other hand, in the sus-
ceptible mice, IL-4, IL-6, and IL-10 were responsible for
the suppression of iNOS-associated mechanisms and dif-
ferentiation of M2-MΦ [30, 78].
Dendritic cells (DCs) and MΦ are important APCs that
establish a bridge between innate and adaptive immunity.
These cells present foreign antigens to helper T cells through
class II molecules of major histocompatibility complex
(MHCII) while these and other cell types can present anti-
gens to cytotoxic T cells through class I molecules of major
histocompatibility complex (MHCI). In addition to MHC
molecules, costimulatory molecules are essential for T cell
suitable activation. Downregulation of costimulatory mole-
cules leads to impairment of signaling pathways and defec-
tive immune responses [79].
Several studies have shown that DCs can play a dichoto-
mic functional role in the modulation of the host immune
response, affecting the adaptive immune response and the
disease outcome [78]. In L. amazonensis and L. braziliensis
cutaneous lesions, dermal DCs (also called Langerhans cells)
play distinct roles. In L. amazonensis patients, DCs are
related to a Th2-type immune response, while in L. brazilien-
sis patients, DCs are associated with a protective Th1
immune response [79].
On the other way, after in vitro restimulation, monocytes
isolated from patients with CL caused by L. braziliensis
showed a low expression of costimulatory molecules B7-1
(CD80) and B7-2 (CD86). Since costimulatory molecules
are crucial for a proper T cell activation, L. braziliensis para-
sites appear to be able to regulate the patient immune
response [80].
Like MΦ, Leishmania also interferes with intracellular
signaling in DCs [73, 78]. Modulation of DC activation by
Leishmania parasites appears to be species-specific [30, 78].
Experimental studies with L. major, L. mexicana, L. amazo-
nensis, and L. braziliensis suggested that migratory DCs
increase the expression of MHC and costimulatory molecules
[30, 73, 78]. Histopathological observations of human skin
biopsies reveal variation in severity of the skin lesions, which
may be related to the density levels of DC subsets exhibiting
diverse phenotype that by directing the T cell immune
response may affect disease severity [3, 81, 82] (Table 2).
In experimental models, DCs process and provide the
first contact of Leishmania antigens to T cells, leading to a
preferential stimulation of IFN-γ produced by CD4+ T cells
[30, 82, 83]. On the other hand, other studies performed in
L. major-infected mice place in evidence that dermal DC
may induce the expansion of the Treg cell subset [84].
Although the role of DCs in CL is very complex, these
cells can be used to develop novel avenues that can lead to
the generation of alternative therapies and therapeutic vac-
cines to improve the treatment of infected patients [85].
DCs and MΦs express PRRs that allow parasite detec-
tion on host skin. TLRs are the most studied, and some of
them, such as TLR3, TLR4, TLR7, and TRL9 have shown
to play a key role in innate sensing and recognition of
Leishmania by those cells [81]. This recognition is crucial
to initiate the inflammatory response and control of para-
site replication [30, 80].
After in vitro restimulation with parasite antigens, mono-
cytes isolated from patients with LC caused by L. braziliensis
showed upregulation of TLR9. Furthermore, it was found an
association between the higher frequency of TLR9+ mono-
cytes and lesion severity. The intracellular sensor TLR9, a
transmembrane protein of endosomal compartments, binds
to pathogen DNA triggering signal pathways that lead to a
proinflammatory response. Thus, the upregulation of this
sensor in CL patients points towards a release of proinflam-
matory cytokines, which do not seem to have a beneficial
effect in reducing disease severity [80].
3.5. Interaction of Proinflammatory and Regulatory
Lymphocyte Subsets Seems to Be the Hallmark of Cutaneous
Leishmaniasis. B and T cells are key components of acquired
immunity. B cells are responsible for generating antigen-
specific antibodies (humoral response), and since they are
APCs, they can also play a role in the activation of T cells
[86–88]. These cells become activated after exposure to for-
eign antigens, which are internalized leading to the replica-
tion and differentiation of effector B cells and antibody
released [30, 86]. Several studies suggest that B cells might
be involved in the exacerbation of Leishmania infections,
including cutaneous disease caused by L. tropica, L. mexi-
cana, L. major, L. braziliensis, and L. amazonensis, though
the mechanism behind it is still unknown [87, 89, 90].
However, studies performed with L. major in resistant
rodent models (C3H/HeN and C57BL/6) suggest that B cells
might have a role in the development of immunity against
Leishmania infection [91, 92]. Furthermore, Mukbel et al.
[93] showed that soluble factors, like species-specific immu-
noglobulins, and both CD4+ T and B cells derived from L.
major-infected mice that healed the infection played a key
role in killing L. amazonensis intracellular parasites. Also, a
more recent study reported by Gibson-Corley [94] showed
that B cells from C3HeB/FeJ mice coinfected with L. major
and L. amazonensis promote parasite killing while B cells
from coinfected C57BL/6 mice were ineffective in controlling
infection. Although, action mechanism of B cells is not well
elucidated, these findings may indicate that B cells can be a
good target for development of a therapeutic for dermal
leishmaniasis, since these cells seem to have a role in CL con-
trol in resistant mouse models [95].
The control of Leishmania infection and disease progres-
sion has long been associated with the generation of proin-
flammatory and anti-inflammatory immune response [30].
A sustained Th1 response characterized by elevated IL-12,
IL-2, IFN-γ, and TNF-α and downmodulation of IL-4 and
IL-10 production promotes MΦ activation (Figure 4) and
seems to be crucial for host control of Leishmania parasite
burden and clinical cure [30, 82, 83].
On the other hand, Th2-related cytokines (IL-4, IL-5, IL-
10, and IL-13) inhibit MΦ activation, contributing to parasite
survival [30, 83, 85].
In some CL clinical forms, a mixed Th1/Th2 immune
response occurs during active infection, tending Th2
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response to be dominant when both types of responses are
activated [10]. The expansion of Th2 response is associated
with the progression and chronicity of cutaneous lesion that
is frequently refractory to classical leishmanial treatment,
leading to severe mutilations [10, 83, 85].
Studies evaluating the production of cytokines in CL
patients caused by L. guyanensis have shown high levels
of IL-2 and IFN-γ [7]. In lesions, it has been detected a
high density of Th2-related cytokines, particularly of IL-
13. Moreover, these patients also can exhibit reduced or
nondetectable antigen recognition associated with high
levels of IL-10 and IL-5 and also lower specific antibody
titers. In conclusion, enhanced Th2-type cytokines, which
restrain Th1-type response, lead to an immune environ-
ment permissive to parasite replication [7, 96, 97]. Thus,
L. guyanensis infection affects the expansion of antigen-
specific T lymphocyte clones, causing low lymphocyte
proliferation and decreasing IFN-γ production. Limited
cellular and humoral responses during L. guyanensis infec-
tion may explain a high parasitic load and the recurrence
of the disease [7].
Advances in the understanding of CL progression indi-
cate that cellular interactions are more complex than the
Th1/Th2 paradigm. Cutaneous Leishmania infection follows
a complex set of interactions that can lead to the differentia-
tion of the Th17 cell subset, which is characterized by
releasing IL-17 [40, 98]. This cytokine, recognized as a proin-
flammatory modulator, induces other cells to release inflam-
matory mediators that ultimately promote PMN recruitment
to the infection site, sustaining an inflammatory environ-
ment that can be associated with lesion persistence.
LC patients infected with L. amazonensis or L. guyanen-
sis exhibited higher levels of Th17 lymphocytes [40]. In
human infections caused by L. major, L. tropica, L. amazo-
nensis, L. braziliensis, L. guyanensis, or L. panamensis was
observed a high IL-17 production, pointing towards PMN
recruitment and MΦ activation, which can be related to
disease development and lesion severity [40, 99]. In murine
studies, Th17 cells were associated with tissue destruction
[40, 51, 88, 100].
Regulatory T (Treg) lymphocytes are considered a crucial
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Figure 4: Activation of host immunity by cutaneous species of Leishmania. After skin infection, Leishmania promastigotes are uptake by
phagocytes. IL-12 is secreted by activated DCs, and parasite antigens are presented by APCs, resulting in lymphocyte activation and
secretion of proinflammatory (IL-2, IFN-γ, and TNF-α) cytokines that can activate MΦ microbicide mechanisms, leading to parasite
inactivation. When IL-4, IL-5, and IL-13 predominate parasite replicates, allowing disease establishment. Differentiation of Th17
lymphocytes lead to a strong inflammatory environment that could cause tissue damage. Regulatory T cells inhibit lymphocyte activity
promoting immune homeostasis and favoring disease progress. CL: cutaneous leishmaniasis; DC: dendritic cells, IFN: interferon; IL:
interleukin; MΦ: macrophages; N: neutrophils; NO: nitric oxide; Th: T helper cell; Th0: naïve T cells; TNF: tumor necrosis factor; Treg:
regulatory T cells.
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regulating disease pathology. The role of Tregs in the spec-
trum of CL immune responses varies across Leishmania spe-
cies [40, 88, 100]. In L. major-infected mice, Tregs play
varying roles in the disease outcome depending upon the
genetic background and susceptibility of the host [101].
However, in the case of L. panamensis infection, Treg cells
play a role in downregulating inflammatory cytokines, which
appear to limit host cell recruitment leading to reduction of
lesion size [101]. Hence, the role of Tregs and also of Th17
in CL is unclear, warranting further investigations able to
evaluate cell dynamic and better understand the potential
of being used as biomarkers of disease severity and a target
for drug treatment.
L. major and L. braziliensis in vivo studies bring evi-
dences that IL-10 subfamily is essential for the wound healing
process, maintaining skin repair properties and limiting
pathology independent of parasite control [85]. Other regu-
latory mechanisms mediated by cytokines must be explored
in future studies for the control of Leishmania-induced
immunopathology [102, 103].
Furthermore, it was reported that CL patients infected
by L. braziliensis can present CD4-CD8- (DN) T lympho-
cytes expressing αβ T cell receptors (TCR) and DN T cells
expressing γδ TCR. While αβ DN T cell subset was asso-
ciated with a more inflammatory environment, leading to
antiparasitic activation of MΦ, γδ DN T cells seem to play
a regulatory role, favoring the reduction of inflammatory
response [103].
In CL, a proper local inflammatory immune response is
crucial to contain and reduce parasite expansion. However,
an extensive or excessive inflammatory response can cause
tissue damage. Thus, the simultaneous finding of proinflam-
matory and regulatory cell subpopulations in CL patients
seems to contribute to the balance between a protective
immune response against the parasite and the natural intrin-
sic response that ensure the immune homeostasis.
NK T (NKT) cells, a specialized subpopulation of T lym-
phocytes, also seem to play a role during the early stages of
Leishmania infections [91, 104, 105] (Figure 4). However,
in L. major-infected mice, it was demonstrated that NKT
cells appear to control parasite burden in skin lesions and
in the spleen, but not in the lymph nodes [54], pointing
towards an organ-specific role for these cells. Moreover, in
the dermal lesions of L. braziliensis-infected patients, NKT
cells with cytotoxic activity were identified [104].
4. Challenges of Prevention, Diagnosis, and
Treatment of Cutaneous Leishmaniasis
Minimizing CL impact relies on prevention, diagnosis, and
treatment, the three primary steps that must integrate devel-
oping new strategies for effective leishmaniasis control.
Prevention is the first pillar that needs to be ensured to
achieve control of the disease. It encompasses (i) the reduc-
tion of population exposition to parasite vector, (ii) measures
to diminish the role of vector and reservoirs in parasite trans-
mission, (iii) awareness and education of the population at
risk for this parasitic disease, (iv) availability of basic health
care, and (v) monitoring of disease spread and incidence.
Vector control relies mostly on the use of insecticides,
besides being toxic and needing a regular reapplication,
which is a hassle for populations with low income and also
generate a significant increase of insecticide-resistant vectors.
Furthermore, the main reservoirs of the parasite are silvatic
animals that can interact with the populations, which also
increase the difficulty in controlling these parasites.
Monitoring of CL still is not an easy task since social
stigma, war, poverty, and scarcity of access to health care
largely affects most of the endemic regions that are associated
with lack of equipment and of trained staff further aggravate
these difficulties.
The diagnosis and treatment are interconnected, since
the stage of disease progression and diagnosis accuracy
highly influence the treatment efficacy. An early and accurate
diagnosis and effective patient management are essential to
reduce parasite transmission and CL increase.
In CL endemic areas, the accuracy of diagnosis must be
made in the earlier clinical presentation to avoid the compli-
cations of advanced disease [106]. Specific approaches to
treat CL patients have to take in consideration the etiologic
agent, patient immune competence, clinical features, and
arising complications in the course of Leishmania infection
[11, 19]. Atypical infections may require an accurate differen-
tial diagnosis with other possible coexisting infections, such
as leprosy, tuberculosis, fungal infections, ecthyma, furuncle,
carbuncle, North American blastomycosis, paracocciomyco-
sis, yaws, prototheca infection, condyloma acuminate, sporo-
trichosis, syphilis, lupus vulgaris, cutaneous furuncular
myiasis, tungiasis, xanthoma tuberosum, sarcoidosis, pyo-
derma gangrenosum, and neoplasm [107]. Conventionally,
the prompt CL diagnosis is obtained by the identification of
amastigotes forms (round intracellular forms with 1.5μm
to 3μm) of Leishmania in biopsy samples of skin lesion (gold
standard) by optical microscopic observation [1]. Other
methodologies may be either applied to the diagnosis of
leishmaniasis, like skin histological analyses, in vitro biopsy
culture, and molecular diagnosis [25]. Occasionally, the
leishmanin skin test (LST), also called the Montenegro skin
test (MST) and delayed-type hypersensitivity (DTH), is used
in CL as a marker of cellular immune response (Table 2).
When CL diagnosis has been unequivocally established, it is
necessary to apply specific targeted therapy and manage the
patient to control the infection [12, 14]. In some cases, it is
necessary to monitor adverse effects including myalgia, gas-
trointestinal disturbances, headache, anorexia, asthenia,
fever, neurological alterations, and arrhythmia and also to
use the medical imaging techniques, like magnetic resonance
imaging (MRI) to show no cartilaginous destruction or para-
nasal involvement in severe cases [12, 108].
Antileishmanial drugs applicable to CL are limited and
display severe side effects, elevated costs, and usually require
prolonged treatments [109]. The species of Leishmania
involved in the infection, parasite resistance, and concomi-
tant infections are key factors that influence the efficacy of
the treatment [110, 111]. Other treatment possibility is the
use of thermotherapy; nevertheless, this technique is not
widely available due to the cost of the devices and procedures
required and the need of skilled health professionals to
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perform the treatment [112]. Recent studies about the spe-
cific interventions to treat CL in children provide evidences
of the scarcity of data available to support treatment recom-
mendations for this age range and of the unmet need to
develop and test better treatment options for this vulnerable
group [113].
The availability of effective, low cost, and safe treat-
ments like prophylactic vaccines, drugs and therapeutic
vaccines for cutaneous infection is not yet available for
human leishmaniasis. Furthermore, other insurgent issues
such as climate changes, migration of populations, and
permissiveness of vectors can make more complex CL con-
trol, promoting disease spreading [16]. Climate changes can
lead to the spreading of the vectors to nonendemic regions
[1, 114]. The dispersion of the vector allied with high vec-
torial capacity and permissiveness can facilitate the adapta-
tion of the parasite in nonendemic areas, leading to the
generation of new foci and increasing the risk of parasite
transmission [3, 115, 116]. Furthermore, economic prob-
lems, natural disasters, and wars associated with mass
migration and tourist travellers can lead to an increased
risk of infection exposure [4, 20, 117].
5. Closing Remarks
Cutaneous leishmaniasis is an important public health prob-
lem worldwide. The spectrum of Leishmania infection can be
subclinical, localized and disseminated, and relies on the
immune competence of the host and on the infectivity of par-
asite species.
The fact of CL present high incidence mainly in areas
with lack of economic resources, insufficient trained health
professionals, and low awareness for the health issue of leish-
maniasis allied with the lack of highly effective vector and
reservoir control, treatments and no availability of a vaccine,
creates an environment that promotes the CL propagation,
turning the disease in pressing concern global health.
Together with the human description of the specific
immune response, animal models have been used to exten-
sively characterize the immune response to parasite infec-
tions caused by cutaneous species of Leishmania. Therefore,
the investment in CL additional studies is urgent and essen-
tial, underlying the factors regulating immune pathological
responses, which are needed for the implementation of more
efficient and integrated control strategies and therapeutics.
These efforts are indispensable for the populations affected
by the disease, which are in desperate need of affordable
and effective alternatives to the available treatments that are
associated with parasite resistance and severe toxic effects.
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